Epigen Pharmaceuticals Overview
- Latest Deal Type
Out of Business
Epigen Pharmaceuticals General Information
Developer of cardiac reperfusion therapies designed to prevent ischemia-reperfusion injury. The company's therapies involves the use of histone deacetylase (HDAC) inhibitors for reducing myocardial infarct size following acute myocardial infarction and restoring normal blood flow, thereby assisting physicians with an effective pharmaceutical intervention for protecting the cardiomyocyte from reperfusion injury.
Want to dig into this profile?
We’ll help you find what you need
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog »
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »